Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2019 Jun 25;3(12):1826-1836.
doi: 10.1182/bloodadvances.2019000050.

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission

Armin Rashidi  1 , Mehdi Hamadani  2 , Mei-Jie Zhang  2   3 , Hai-Lin Wang  2 , Hisham Abdel-Azim  4 , Mahmoud Aljurf  5 , Amer Assal  6 , Ashish Bajel  7 , Asad Bashey  8 , Minoo Battiwalla  9 , Amer M Beitinjaneh  10 , Nelli Bejanyan  11 , Vijaya Raj Bhatt  12 , Javier Bolaños-Meade  13 , Michael Byrne  14 , Jean-Yves Cahn  15 , Mitchell Cairo  16 , Stefan Ciurea  17 , Edward Copelan  18 , Corey Cutler  19 , Andrew Daly  20 , Miguel-Angel Diaz  21 , Nosha Farhadfar  22 , Robert P Gale  23 , Siddhartha Ganguly  24 , Michael R Grunwald  18 , Theresa Hahn  25 , Shahrukh Hashmi  5   26 , Gerhard C Hildebrandt  27 , H Kent Holland  8 , Nasheed Hossain  28 , Christopher G Kanakry  29 , Mohamed A Kharfan-Dabaja  30 , Nandita Khera  31 , Yener Koc  32 , Hillard M Lazarus  33 , Jong-Wook Lee  34 , Johan Maertens  35 , Rodrigo Martino  36 , Joseph McGuirk  24 , Reinhold Munker  37 , Hemant S Murthy  22 , Ryotaro Nakamura  38 , Sunita Nathan  39 , Taiga Nishihori  40 , Neil Palmisiano  41 , Sagar Patel  42 , Joseph Pidala  43 , Rebecca Olin  44 , Richard F Olsson  45   46 , Betul Oran  47 , Olov Ringden  48 , David Rizzieri  49 , Jacob Rowe  50 , Mary Lynn Savoie  20 , Kirk R Schultz  51 , Sachiko Seo  52 , Brian C Shaffer  53 , Anurag Singh  24 , Melhem Solh  8 , Keith Stockerl-Goldstein  54 , Leo F Verdonck  55 , John Wagner  41 , Edmund K Waller  56 , Marcos De Lima  57 , Brenda M Sandmaier  58 , Mark Litzow  59 , Dan Weisdorf  60 , Rizwan Romee  19 , Wael Saber  2
Affiliations
Comparative Study

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission

Armin Rashidi et al. Blood Adv. .

Abstract

HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy-based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P = .15), leukemia-free survival (P = .50), nonrelapse mortality (P = .16), relapse (P = .90), or grade II-IV acute GVHD (P = .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P < .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease-donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy-based Haplo-HCT vs MSD using calcineurin inhibitor-based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Outcomes after Haplo-HCT vs MSD in patients with AML in CR1. Adjusted curves for OS (A), LFS (B), relapse (C), NRM (D), grade II-IV acute GVHD (E), and chronic GVHD (F).
See this image and copyright information in PMC

References

    1. Szydlo R, Goldman JM, Klein JP, et al. . Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15(5):1767-1777. - PubMed
    1. Howard CA, Fernandez-Vina MA, Appelbaum FR, et al. . Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2015;21(1):4-7. - PMC - PubMed
    1. Kasamon YL, Bolaños-Meade J, Prince GT, et al. . Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015;33(28):3152-3161. - PMC - PubMed
    1. Bashey A, Zhang M-J, McCurdy SR, et al. . Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide. J Clin Oncol. 2017;35(26):3002-3009. - PMC - PubMed
    1. Giannotti F, Labopin M, Shouval R, et al. . Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. J Hematol Oncol. 2018;11(1):110. - PMC - PubMed

Publication types

MeSH terms